NCT04331275

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

Viral Specific T-cells (VSTs) for Treatment of Viral Infections After Solid Organ Transplant

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Children's Hospital Medical Center, Cincinnati · Academic / Other
• Sex: All
• Age: 1 Day
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant (SOT). VSTs are cells specially designed to fight viral infections that may happen after a solid organ transplant. These cells are created from a blood sample collected from the study participant. Solid organ transplant and the use of immunosuppressive medications reduces the body's ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Reduction of immunosuppression may put the organ at risk of rejection. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study the investigators are trying to find a better way to treat these infections and minimize complications.

Conditions

• Solid Organ Transplant
• Viral Infection

Interventions

Type	Name	Description
BIOLOGICAL	Viral Specific T-cells (VSTs)	VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.

Timeline

• Start date: 2020-08-18
• Primary completion: 2026-09-01
• Completion: 2028-09-01
• First posted: 2020-04-02
• Last updated: 2025-11-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study